LifeMD (LFMD) announced it is now offering Novo Nordisk’s (NVO) Wegovy pill, the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health, through its end-to-end telehealth platform. Eligible patients can access the Wegovy pill for as little as $149 per month, further expanding LifeMD’s portfolio of branded obesity treatments, LifeMD said. This announcement broadens LifeMD’s long-standing collaboration with Novo Nordisk.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD’s Strategic Positioning and Financial Health Reinforce Buy Rating Despite Revenue Miss
- LifeMD price target lowered to $9 from $13 at H.C. Wainwright
- LifeMD price target lowered to $6 from $8 at Mizuho
- LifeMD price target lowered to $8 from $12 at KeyBanc
- LifeMD Earnings Call: Growth Amid Challenges